Literature DB >> 35522226

Experimental study on novel biodegradable Zn-Fe-Si alloys.

Yuxin Zeng1, Zeyi Guan1, Chase S Linsley2, Shuaihang Pan1, Jingke Liu1, Benjamin M Wu2,3,4,5, Xiaochun Li1,3.   

Abstract

Bioabsorbable metals are increasingly attracting attention for their potential use as materials for degradable implant devices. Zinc (Zn) alloys have shown great promises due to their good biocompatibility and favorable degradation rate. However, it has been difficult to maintain an appropriate balance among strength, ductility, biocompatibility, and corrosion rate for Zn alloys historically. In this study, the microstructure, chemical composition, mechanical properties, biocompatibility, and corrosion rate of a new ternary zinc-iron-silicon (Zn-Fe-Si) alloy system was studied as a novel material for potential biodegradable implant applications. The results demonstrated that the in situ formed Fe-Si intermetallic phases enhanced the mechanical strength of the material while maintaining a favorable ductility. With Fe-Si reinforcements, the microhardness of the Zn alloys was enhanced by up to 43%. The tensile strength was increased by up to 76% while elongation to failure remained above 30%. Indirect cytotoxicity testing showed the Zn-Fe-Si system had good biocompatibility. Immersion testing revealed the corrosion rate of Zn-Fe-Si system was not statistically different from pure Zn. To understand the underlying phase formation mechanism, the reaction process in this ternary system during the processing was also studied via phase evolution and Gibbs free energy analysis. The results suggest the Zn-Fe-Si ternary system is a promising new material for bioabsorbable metallic medical devices.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  Zn-Fe-Si alloys; biocompatibility; biodegradable; in situ formed intermetallic; mechanical properties

Mesh:

Substances:

Year:  2022        PMID: 35522226      PMCID: PMC9378461          DOI: 10.1002/jbm.b.35075

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.405


  33 in total

Review 1.  The operation of the century: total hip replacement.

Authors:  Ian D Learmonth; Claire Young; Cecil Rorabeck
Journal:  Lancet       Date:  2007-10-27       Impact factor: 79.321

2.  Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.

Authors:  Michael Haude; Hüseyin Ince; Alexandre Abizaid; Ralph Toelg; Pedro Alves Lemos; Clemens von Birgelen; Evald Høj Christiansen; William Wijns; Franz-Josef Neumann; Christoph Kaiser; Eric Eeckhout; Soo Teik Lim; Javier Escaned; Hector M Garcia-Garcia; Ron Waksman
Journal:  Lancet       Date:  2015-10-12       Impact factor: 79.321

3.  Novel Zinc / Tungsten Carbide Nanocomposite as Bioabsorbable Implant.

Authors:  Zeyi Guan; Chase S Linsley; Injoo Hwang; Gongcheng Yao; Benjamin M Wu; Xiaochun Li
Journal:  Mater Lett       Date:  2019-12-28       Impact factor: 3.423

4.  In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris - DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial.

Authors:  Hector M Garcia-Garcia; Michael Haude; Kayode Kuku; Alexandre Hideo-Kajita; Hüseyin Ince; Alexandre Abizaid; Ralph Tölg; Pedro Alves Lemos; Clemens von Birgelen; Evald Høj Christiansen; William Wijns; Javier Escaned; Jouke Dijkstra; Ron Waksman
Journal:  Int J Cardiol       Date:  2017-12-28       Impact factor: 4.164

Review 5.  Recent advances and directions in the development of bioresorbable metallic cardiovascular stents: Insights from recent human and in vivo studies.

Authors:  Alexander A Oliver; Malgorzata Sikora-Jasinska; Ali Gökhan Demir; Roger J Guillory
Journal:  Acta Biomater       Date:  2021-04-03       Impact factor: 8.947

6.  Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.

Authors:  Michael Haude; Raimund Erbel; Paul Erne; Stefan Verheye; Hubertus Degen; Paul Vermeersch; Neil Weissman; Francesco Prati; Nico Bruining; Ron Waksman; Jacques Koolen
Journal:  EuroIntervention       Date:  2016-06-12       Impact factor: 6.534

7.  In vitro and in vivo degradation behavior of Mg-2Sr-Ca and Mg-2Sr-Zn alloys.

Authors:  Kai Chen; Xinhui Xie; Hongyan Tang; Hui Sun; Ling Qin; Yufeng Zheng; Xuenan Gu; Yubo Fan
Journal:  Bioact Mater       Date:  2020-02-25

8.  Test conditions can significantly affect the results of in vitro cytotoxicity testing of degradable metallic biomaterials.

Authors:  Eva Jablonská; Jiří Kubásek; Dalibor Vojtěch; Tomáš Ruml; Jan Lipov
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379

Review 9.  Review on iron and its importance for human health.

Authors:  Nazanin Abbaspour; Richard Hurrell; Roya Kelishadi
Journal:  J Res Med Sci       Date:  2014-02       Impact factor: 1.852

10.  BIOSOLVE-IV-registry: Safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients.

Authors:  Stefan Verheye; Adrian Wlodarczak; Piero Montorsi; Jan Torzewski; Johan Bennett; Michael Haude; Gregory Starmer; Thomas Buck; Marcus Wiemer; Amin A B Nuruddin; Bryan P-Y Yan; Michael K-Y Lee
Journal:  Catheter Cardiovasc Interv       Date:  2020-09-03       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.